Active, Not Recruiting
Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
NCT04762979
- Conditions
- HER2-negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma, PIK3CA Mutant Metastatic Breast Cancer
- Locations
-
- University of Illinois Cancer Center Chicago, Illinois, United States
- University of Nebraska Medical Center Omaha, Nebraska, United States
- Penn State Cancer Institute Hershey, Pennsylvania, United States
- University of Wisconsin Madison, Wisconsin, United States